Dysregulation of IFN pathways is an important feature that can be potentially used as a serum biomarker for diagnosis and targeting of new treatments in this complex autoimmune disease. Frontiers in Immunology, 20 September 2013. (Also see: Sjögren's Treatments)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.